Xu S, Ilyas I, Little PJ, Hong, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, Harding IC, Ebong EE, Cameron SJ, Stewart AG, Weng J. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924–67. https://doi.org/10.1124/pharmrev.120.000096.

Article  CAS  PubMed  Google Scholar 

Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840–4. https://doi.org/10.1161/01.res.87.10.840.

Article  CAS  PubMed  Google Scholar 

Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J. 1987;1(6):441–5. https://doi.org/10.1096/fasebj.1.6.3315807.

Article  CAS  PubMed  Google Scholar 

Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno G, Davila R, Morsch A, Da Silva Stein F, Campos GGD. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018. https://doi.org/10.1186/s12872-018-0757-9.

Article  PubMed  PubMed Central  Google Scholar 

Butler RJ, Morris AD, Belch JJF, Hill AJ, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2018;35(3):746–51. https://doi.org/10.1161/01.hyp.35.3.746.

Article  Google Scholar 

Grassi D, Pontremoli R, Bocale R, Ferri C, Desideri G. Therapeutic approaches to chronic hyperuricemia and gout. High Blood Press Cardiovasc Prev. 2014;21:243–50. https://doi.org/10.1007/s40292-014-0051-6.

Article  CAS  PubMed  Google Scholar 

Britnell SR, Chillari KA, Brown JN. The role of xanthine oxidase inhibitors in patients with history of stroke: a systematic review. Curr Vasc Pharmacol. 2018;16(6):583–8. https://doi.org/10.2174/1570161115666170919183657.

Article  CAS  PubMed  Google Scholar 

Dickson K, Yeung CA. PRISMA 2020 updated guideline. Br Dent J. 2020;232(11):760–1. https://doi.org/10.1038/s41415-022-4359-7.

Article  Google Scholar 

Chapman SJ, Dossa F, De Groof EJ, Keane C, Van Ramshorst GH, Smart NJ. The AMSTAR -2 critical appraisal tool and editorial decision-making for systematic reviews: retrospective, bibliometric study. Learned Publishing. 2022;35(4):529–38. https://doi.org/10.1002/leap.1463.

Article  Google Scholar 

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https://doi.org/10.1136/bmj.d5928.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  PubMed  PubMed Central  Google Scholar 

Greig D, Alcaíno H, Castro P, Garcia L, Verdejo H, Navarro M, López RM, Mellado R, Tapia FM, Gabrielli L, Nogerol C, Chiong M, Godoy I, Lavandero S. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant. 2011;30(4):408–13. https://doi.org/10.1016/j.healun.2010.10.003.

Article  PubMed  Google Scholar 

Xiao J, Sb D, Q S, Li J, Gy K, Js W, Ma Y. Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. PubMed. 2016;20(4):756–61.

CAS  Google Scholar 

Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, Papageorgiou NS, Papadimitriou C, Dimopoulos MA, Stefanadis C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7. https://doi.org/10.1016/j.atherosclerosis.2010.11.002.

Article  CAS  PubMed  Google Scholar 

Lim TK, Noman A, Choy AM, Khan F, Struthers AD, Lang CC. The APEX trial: effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. Cardiovasc Ther. 2017;36(1): e12311. https://doi.org/10.1111/1755-5922.12311.

Article  CAS  Google Scholar 

Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926–32. https://doi.org/10.1016/j.jacc.2012.09.066.

Article  CAS  PubMed  Google Scholar 

Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011;58(8):820–8. https://doi.org/10.1016/j.jacc.2010.12.052.

Article  CAS  PubMed  Google Scholar 

Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, George J, Struthers AD. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284–93. https://doi.org/10.1016/j.jacc.2013.07.074.

Article  CAS  PubMed  Google Scholar 

Dogan A, Yarlioglues M, Kaya M, Karadağ Z, Doğan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan A, Kalay N. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2010;20(3):182–7. https://doi.org/10.3109/08037051.2010.538977.

Article  CAS  PubMed  Google Scholar 

Yiginer O, Özçelik F, Inanc T, Aparci M, Özmen N, Cingözbay BY, Kardesoglu E, Süleymanoğlu S, Şener G, Cebeci BS. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2007;97(5):334–40. https://doi.org/10.1007/s00392-007-0636-3.

Article  CAS  PubMed  Google Scholar 

Rutherford E, Ireland S, Mangion K, Stewart G, MacGregor MS, Roditi G, Woodward R, Gandy SJ, Houston JG, Jardine AG, Rauchhaus P, Witham MD, Mark PB, Struthers AD. A randomized, controlled trial of the effect of allopurinol on left ventricular mass index in hemodialysis patients. Kidney Int Reports. 2021;6(1):146–55. https://doi.org/10.1016/j.ekir.2020.10.025.

Article  Google Scholar 

Kao M, Ang DSC, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22(7):1382–9. https://doi.org/10.1681/asn.2010111185.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayram D, Sezer MT, Inal S, Altuntaş A, Kidir V, Orhan H. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2014;19(3):443–9. https://doi.org/10.1007/s10157-014-1012-z.

Article  CAS  PubMed  Google Scholar 

Jalal D, Decker E, Perrenoud L, Nowak KL, Bispham NZ, Mehta T, Smits G, You Z, Seals DR, Chonchol M, Johnson RJ. Vascular function and uric acid-lowering in stage 3 CKD. J Am Soc Nephrol. 2016;28(3):943–52. https://doi.org/10.1681/asn.2016050521.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borgi L, McMullan CJ, Wohlhueter AL, Curhan GC, Fisher ND, Forman JP. Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial. Hypertension. 2017;69(2):243–8. https://doi.org/10.1161/hypertensionaha.116.08488.

Article  CAS  PubMed  Google Scholar 

Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94. https://doi.org/10.2215/cjn.11451210.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robertson AJ, Struthers AD. A randomized controlled trial of allopurinol in patients with peripheral arterial disease. Can J Cardiol. 2016;32(2):190–6. https://doi.org/10.1016/j.cjca.2015.05.010.

Article  PubMed  Google Scholar 

Witham MD, Clarke C, Hutcheon A, Gingles C, Gandy SJ, Priba L, Nicholas RS, Cavin I, Sumukadas D, Struthers AD, George J. Effect of allopurinol on phosphocreatine recovery and muscle function in older people with impaired physical function: a randomised controlled trial. Age And Ageing. 2020;49(6):1003–10. https://doi.org/10.1093/ageing/afaa061.

Article  PubMed  PubMed Central  Google Scholar 

Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, Feig DI, Redden DT, Muntner P, Foster PP, Biggers-Clark S, Mudano AS, Sattui SE, Saddekni MB, Bridges SL, Saag KG. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 2021;73(8):1514–22. https://doi.org/10.1002/art.41749.

Article  CAS  PubMed  Google Scholar 

O’Driscoll J, Green D, Rankin J, Taylor RR. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol. 1999;26(10):779–83. https://doi.org/10.1046/j.1440-1681.1999.03125.x.

Article  PubMed  Google Scholar 

George J, Carr E, Davies J, Belch JJF, Struthers AD. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–16. https://doi.org/10.1161/circulationaha.106.651117.

Article  CAS  PubMed  Google Scholar 

Farquharson C, Butler RJ, Hill AJ, Belch JJF, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106(2):221–6. https://doi.org/10.1161/01.cir.0000022140.61460.1d.

Article  CAS